After nearly two decades treating patients with neuromodulators, I still hear the same question: "What's the difference between all these toxins?" The honest answer is that the differences matter—not because one product is universally superior, but because each has characteristics that make it better suited for certain anatomical areas, injection techniques, and patient response patterns.
What makes each neuromodulator molecularly distinct?
All four products—Botox (onabotulinumtoxinA), Dysport (abobotulinumtoxinA), Xeomin (incobotulinumtoxinA), and Letybo (letibotulinumtoxinA)—contain botulinum toxin type A as their active ingredient. They all work by blocking acetylcholine release at the neuromuscular junction, temporarily weakening targeted muscles. The differences lie in formulation details: accessory proteins, molecular weight, and manufacturing process. Botox and Dysport contain complexing proteins that stabilize the toxin. Xeomin is formulated without these proteins—often called "naked" botulinum toxin—which theoretically reduces the risk of antibody formation, though clinical neutralizing antibody rates remain very low across all products. Letybo, approved by the FDA in October 2024 for glabellar lines, is manufactured using a Hall strain of Clostridium botulinum and has a similar protein-containing profile to Botox. The molecular weight of the toxin complex varies: Dysport's smaller complex may contribute to faster diffusion, while Xeomin's lack of accessory proteins results in a smaller effective molecular footprint.
How do onset speed and duration compare in clinical practice?
Onset and duration are where patients notice real-world differences. Dysport typically shows visible muscle relaxation within 2–3 days, while Botox and Xeomin often take 4–7 days, and full effect for all products peaks around 10–14 days. A 2020 split-face study in Dermatologic Surgery found Dysport achieved glabellar line improvement 1.5 days earlier than Botox on average. Letybo's Phase 3 trials demonstrated onset and duration similar to Botox, with median time to onset around 3–4 days. Duration is highly individual but generally ranges from 3–4 months. Some patients report Dysport wearing off slightly sooner in high-movement areas like the forehead, though a 2019 meta-analysis in Aesthetic Surgery Journal found no statistically significant difference in duration between Botox and Dysport when dosed appropriately. Xeomin's duration matches Botox in most comparative trials. In our clinic, we see substantial variation: patients with faster metabolisms, higher muscle mass, or intense physical activity patterns may metabolize any neuromodulator more quickly. We counsel that 12–16 weeks is the typical reinjection interval regardless of product, though some patients stretch Botox or Xeomin to 18–20 weeks in low-movement areas like the glabella.
What unit conversions and cost differences should patients understand?
Neuromodulator units are not interchangeable. The accepted conversion ratio is approximately 1:1 for Botox, Xeomin, and Letybo, and roughly 2.5–3:1 for Dysport (meaning 50 units of Dysport equals about 20 units of Botox). This is not an exact science—published ratios vary from 2:1 to 4:1—and experienced injectors adjust based on individual muscle strength and treatment area. For example, treating glabellar frown lines typically requires 20–25 units of Botox or Xeomin, 50–60 units of Dysport, or 20–25 units of Letybo. Forehead lines may need 10–20 units of Botox/Xeomin/Letybo or 30–50 units of Dysport. Crow's feet usually take 10–15 units per side with Botox/Xeomin/Letybo or 30–40 units per side with Dysport. Cost per unit varies by region and clinic, but Dysport is often priced lower per unit to account for the higher unit requirement. In the San Gabriel Valley, typical per-unit pricing ranges from $10–15 for Botox and Xeomin, $4–6 for Dysport, and $10–14 for Letybo. Total treatment cost for a given area ends up similar across products when dosed correctly—frown lines might cost $200–300 regardless of which toxin is used. Patients sometimes assume a lower per-unit price means savings, but the unit requirement determines actual cost.
Which neuromodulator works best for specific facial areas?
Diffusion radius—how far the toxin spreads from the injection point—determines ideal use cases. Dysport has a wider diffusion radius, which can be advantageous for broad areas like the forehead where you want smooth, even coverage without multiple injection points. This same property makes Dysport less ideal for precise work near the eyes or in areas where you want to avoid affecting adjacent muscles. Botox, Xeomin, and Letybo have tighter diffusion, making them better choices for crow's feet, under-eye lines, or lip flips where precision matters. For masseter reduction (jawline slimming), we typically use Botox or Xeomin because the masseter is a large muscle that benefits from controlled, deep placement—though some practitioners prefer Dysport's spread for achieving uniform relaxation across the muscle belly. A 2021 study in Journal of Cosmetic Dermatology comparing Botox and Dysport for masseter reduction found both effective, with no significant difference in jaw width reduction at 3 months, but Dysport required more units. For the lip flip—injecting the orbicularis oris to evert the upper lip—we use very small doses of Botox, Xeomin, or Letybo (1–2 units per side) because diffusion control is critical to avoid weakening the lip's functional movements. Letybo is still establishing its clinical track record in off-label uses, but early adopter feedback suggests performance similar to Botox for most applications.
Does your body build resistance to neuromodulators over time?
Neutralizing antibody formation—true immunologic resistance—is rare but real. It occurs when the immune system produces antibodies that bind and inactivate the toxin before it reaches nerve terminals. Incidence estimates range from 0.1% to 4% depending on product, dosing frequency, and individual immune factors. Xeomin's lack of complexing proteins was specifically designed to reduce this risk. The theory is that accessory proteins can act as antigens, triggering antibody production, while "naked" toxin presents a smaller immunogenic target. However, clinical data show very low antibody rates across all modern formulations, and a 2022 review in Toxins concluded that antibody-mediated resistance is uncommon with contemporary dosing practices. What patients often describe as "resistance" is usually secondary non-response: the product worked initially but seems less effective over time. This can result from underdosing, changes in muscle activity patterns, product storage or reconstitution issues, or the natural adaptation where patients notice lines more as they become accustomed to smoother skin. If we suspect true resistance, we can perform a frontalis or corrugator antibody test (injecting a small dose and observing for muscle weakness) and consider switching to a different formulation. Letybo, as a newer entrant, may offer an alternative for patients who have developed antibodies to other toxins, though cross-reactivity is possible since all products contain botulinum toxin type A.
How do you decide which neuromodulator to use?
We select based on treatment area anatomy, desired diffusion, patient history, and cost considerations. For broad areas like the forehead or masseters in patients who want comprehensive smoothing, Dysport's wider spread can be efficient. For precision areas—crow's feet, under-eye, lip flip, chin dimpling—Botox, Xeomin, or Letybo provide tighter control. If a patient has a history of frequent neuromodulator use or concerns about antibody formation, Xeomin is a logical first choice. If a patient prioritizes faster onset for an upcoming event, Dysport may be preferable. Cost is also legitimate: some patients prefer Dysport because clinics can offer lower per-unit pricing, while others want the established track record of Botox. Letybo is expanding availability as clinics gain access to the newly approved product, and early data suggest comparable efficacy and safety to Botox for glabellar lines. In our clinic, we stock multiple options precisely because no single neuromodulator is optimal for every patient and every indication. We also adjust technique—injection depth, number of points, dose per point—based on the product's diffusion characteristics. A key principle: achieving natural results depends more on injector skill and anatomical understanding than on product selection. An experienced injector can achieve excellent outcomes with any of these four FDA-approved neuromodulators by tailoring technique to the product's properties.
